Status:
COMPLETED
A Study to Assess the Change in Disease State in Adult Participants Being Treated With Oral Upadacitinib Tablets in Participants With Oligo- or Poly-artIcular Psoriatic Arthritis
Lead Sponsor:
AbbVie
Conditions:
Psoriatic Arthritis
Eligibility:
All Genders
18+ years
Brief Summary
Psoriatic arthritis (PsA) is a type of arthritis (swelling and stiffness in the joints) that is frequently seen in trial participants who also have the skin condition psoriasis. It is caused by the bo...
Eligibility Criteria
Inclusion
- Diagnosis of active Psoriatic Arthritis (PsA) upon judgment of the treating physician.
- Swollen joint count (SJC) \>= 1 out of 66 joints.
- Decision on the treatment with Upadacitinib was made prior to any decision to approach the participant to participate in this study.
Exclusion
- Cannot be treated with Upadacitinib according to the local Upadacitinib Summary of Product Characteristics (SmPC).
- Prior treatment with Upadacitinib.
- Currently participating in interventional research or within the last 30 days.
Key Trial Info
Start Date :
February 4 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 26 2023
Estimated Enrollment :
394 Patients enrolled
Trial Details
Trial ID
NCT04758117
Start Date
February 4 2021
End Date
July 26 2023
Last Update
July 17 2024
Active Locations (93)
Enter a location and click search to find clinical trials sorted by distance.
1
Dr. Jonathan D. Chan Inc. /ID# 241611
Vancouver, British Columbia, Canada, V5Z 1J9
2
Manitoba Clinic /ID# 234148
Winnipeg, Manitoba, Canada, R3A 1M3
3
The Waterside Clinic /ID# 234146
Barrie, Ontario, Canada, L4M 6L2
4
Dr. Chrisostomos Kouroukis & Dr. Pauline Boulos MPC /ID# 233565
Dundas, Ontario, Canada, L9H 1B7